Skip to main content

Table 1 Univariate analyses of factors associated with bone metastasis in 252 HCC patients

From: The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis in hepatocellular carcinoma

VariableBone metastasis
HR (95% CI)P
Age (≤51 versus > 51 years)1.021 (0.520–2.004)0.952
Gender (male versus female)1.109 (0.429–2.866)0.830
HBsAg (negative versus positive)0.735 (0.333–1.625)0.447
HCV-Ab (negative versus positive)1.608 (0.219–11.829)0.641
AFP, ng/mL (≤ 20 versus > 20)0.597 (0.295–1.206)0.150
ALT,U/L (≤ 40 versus > 40)1.356 (0.648–2.836)0.419
γ-GT,U/L (≤ 50 versus > 50)1.275 (0.650–2.501)0.480
Liver cirrhosis (no versus yes)1.039 (0.430–2.510)0.933
Child-Pugh score (A versus B)2.714 (0.650–11.336)0.171
Tumor differentiation (I–II versus III–IV)0.464 (0.163–1.317)0.149
Tumor size, cm (≤ 5 versus > 5)0.716 (0.358–1.430)0.344
Tumor number (single versus multiple)1.108 (0.482–2.544)0.810
Tumor encapsulation (complete versus none)4.112 (1.791–9.444)0.001
Vascular invasion (no versus yes)13.116 (6.379–26.969)< 0.001
BCLC stage (0-A versus B-C)18.099 (8.894–36.834)< 0.001
Lnc34a (negative versus positive)9.780 (3.440–27.806)< 0.001
  1. HCC Hepatocellular carcinoma, HBsAg Hepatitis B surface antigen, HCV-Ab Hepatitis C virus antibody, AFP A-fetoprotein, ALT Alanine aminotransferase, γ-GT γ-glutamyl transferase, BCLC-stage Barcelona clinic liver cancer-stage